Trial Profile

INHALE-1st: Technosphere Insulin (Afrezza) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin (Primary) ; Insulin (Primary)
Indications Hyperglycaemia; Type 1 diabetes mellitus
Focus Therapeutic Use
Acronyms INHALE-1st
Sponsors MannKind Corporation

Most Recent Events

23 Jun 2026 According to MannKind Corporation media release, Mankind Corporation has received a grant from Breakthrough T1D (formerly JDRF) through its Industry Discovery and Development Partnership (IDDP) program to support this trial
23 Jun 2026 Status changed from recruiting to active, no longer recruiting as per MannKind Corporation media release
06 May 2026 According to MannKind Corporation media release, pilot phase of the trial has been completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com